Amgen Q2 2023: Revenue up 6% to $7.0B; Non-GAAP EPS rises 8% to $5.00

AMGEN INC

2023-Q2 EPS reported $7.86 revenue$13,091,000,000

Total revenues increased 6% to $7.0B; product sales volume growth of 11% partially offset by FX and price.
GAAP EPS $2.57 (up 5% YoY); Non-GAAP EPS $5.00 (up 8% YoY), driven by record revenues.
Free cash flow $3.8B vs $1.7B in Q2 2022, due to timing of tax payments and higher income.
Pipeline: positive top-line for tarlatamab in small cell lung cancer and LUMAKRAS+Vectibix in colorectal cancer.
Volume growth double-digit for EVENITY, BLINCYTO, Repatha, LUMAKRAS, Vectibix, KYPROLIS, Nplate, AMJEVITA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AMGEN INC reported the second quarter of 2023 results: revenue $7.0 billion, EPS $5.00.

Period: the second quarter of 2023
Revenue: $7.0 billion
EPS: $5.00
Result: reported results

Exact text from the filing

shared today illustrates the rapid progress we are making in advancing our pipeline of potential first-in-class medicines." Key results include: • Total revenues increased 6% to $7.0 billion in comparison to the second quarter of 2022, resulting from a 6% increase in product sales. Produ ct sales growth was driven by 11% volume growth, partially offset by 2% lower

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

AMGEN INC filing history →

Source: SEC EDGAR

accession 0000318154-23-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.